![7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene](/upload/1124/V39981.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Liver Receptor Homolog-1 (LRH-1, NR5A2) and Estrogen Receptors (ERalpha/ERbeta). This compound is an LRH-1 antagonist with an IC50 of 3.1 microM. LRH-1 is a nuclear receptor involved in bile acid synthesis, cholesterol homeostasis, glucose metabolism, and cell proliferation. As a SERM, the Raloxifene core exhibits selective estrogen receptor modulation, acting as an estrogen agonist in bone (preventing osteoporosis) and as an antagonist in breast and uterine tissues. This derivative retains some of these activities.
|
|---|---|
| ln Vitro |
7-[4-(2-Piperidyl)ethoxy]benzoylraloxifene binds to LRH-1's structural domain (LBD)[1].
7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is an LRH-1 antagonist with an IC50 of 3.1 microM. As a Raloxifene derivative, it also exhibits SERM activity, modulating estrogen receptors in a tissue-selective manner. In vitro studies suggest that the compound may possess antioxidant properties. The compound is used to study LRH-1 function and for quality control of Raloxifene drug substance. |
| ln Vivo |
Not applicable (impurity standard/reference material). This compound is not intended for in vivo efficacy studies as a therapeutic agent. It serves as a pharmacopoeial impurity standard (EP Impurity A) for the quantification of related substances in Raloxifene API and finished drug products. Quality control methods (HPLC) are used to ensure that the impurity level is below pharmacopoeial limits (typically <0.5%).
|
| Enzyme Assay |
Cell-free LRH-1 binding assays are performed using a fluorescence polarization (FP) or TR-FRET competitive binding assay format. Recombinant human LRH-1 ligand-binding domain (LBD, 10-20 nM) is incubated with a fluorescently labeled LRH-1 ligand (e.g., Fluormone™, 5 nM) and varying concentrations of 7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene (0.01-100 microM) in assay buffer (20 mM HEPES pH 7.4, 50 mM NaCl, 5 mM CHAPS, 1 mM DTT) for 2-4 hours at 4degC. Fluorescence polarization is measured (excitation 485 nm, emission 520 nm). IC50 values are calculated, and Ki is determined using the Cheng-Prusoff equation.
|
| Cell Assay |
Not applicable (impurity/reference standard, not used in cellular activity assays). For quality control purposes, the compound is used as a reference standard in HPLC analysis. A solution of 7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene in methanol or acetonitrile is injected onto a reversed-phase C18 column (150 × 4.6 mm, 5 microm) with UV detection at 280 nm. The retention time is compared to that of Raloxifene API, and the impurity level is quantified using the area percentage method.
|
| Animal Protocol |
Not applicable (impurity standard, not administered in efficacy studies). For pharmacokinetic studies of Raloxifene, rats or dogs are dosed orally with Raloxifene (1-10 mg/kg). Blood samples are collected at various time points post-dose, and plasma is analyzed for Raloxifene and its impurities, including 7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene, by LC-MS/MS using appropriate internal standards. The impurity concentration is typically low (<0.5% of parent drug levels).
|
| ADME/Pharmacokinetics |
7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is a reference standard for analytical method development. It has a molecular weight of approximately 705 g/mol. As an impurity, it is expected to be present at very low levels (<0.5%) in Raloxifene API. Pharmacokinetics of the impurity are not independently studied; it is assumed to be metabolized similarly to Raloxifene, which undergoes extensive glucuronidation (UGT1A1, UGT1A8, UGT1A9) and enterohepatic recirculation.
|
| Toxicity/Toxicokinetics |
The compound is an impurity standard and is not intended for human consumption. As a reference material, toxicity data are not applicable. The parent drug Raloxifene (Evista) is generally well tolerated; common adverse effects include hot flashes, leg cramps, peripheral edema, and an increased risk of venous thromboembolism (VTE, e.g., DVT/PE). The impurity is not expected to contribute significantly to the toxicity profile of Raloxifene at the trace levels present in API.
|
| References | |
| Additional Infomation |
7-[4-(2-Piperidinyl)ethoxy]benzoyl Raloxifene is a pharmacopoeial impurity (EP Impurity A, also known as Raloxifene 3,7-Diketone) that is used as a reference standard in pharmaceutical quality control. It is also a liver receptor homolog-1 (LRH-1) antagonist, making it a research tool for studying LRH-1 function in metabolism and cancer. This compound is for research use only and not for human therapy.
|
| Molecular Formula |
C42H44N2O6S
|
|---|---|
| Molecular Weight |
704.87356
|
| Exact Mass |
704.292
|
| CAS # |
1159977-58-8
|
| PubChem CID |
18410283
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
8.046
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
51
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZIQUILNLPRCFRB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H44N2O6S/c45-32-13-7-31(8-14-32)41-37(39(47)29-9-15-33(16-10-29)49-27-25-43-21-3-1-4-22-43)35-19-20-36(46)38(42(35)51-41)40(48)30-11-17-34(18-12-30)50-28-26-44-23-5-2-6-24-44/h7-20,45-46H,1-6,21-28H2
|
| Chemical Name |
[6-hydroxy-2-(4-hydroxyphenyl)-7-[4-(2-piperidin-1-ylethoxy)benzoyl]-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~141.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4187 mL | 7.0935 mL | 14.1870 mL | |
| 5 mM | 0.2837 mL | 1.4187 mL | 2.8374 mL | |
| 10 mM | 0.1419 mL | 0.7094 mL | 1.4187 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
